Seyithan TAYSI | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Prof. Dr. Seyithan TAYSI | Molecular Biology | Best Researcher Award 

Professor | Gaziantep University | Turkey

Prof. Dr. Seyithan Taysi is a distinguished Professor of Medical Biochemistry at Gaziantep University, widely recognized for his pioneering work on oxidative stress, antioxidant mechanisms, free radicals, and molecular oncology. He earned his Ph.D. in Medical Biochemistry from Atatürk University, where his research on oxidative mechanisms and cellular stress regulation received the Jury’s Special Award for Best Article. Currently, he leads advanced biochemical research and teaching programs, having completed over ninety-five funded projects and holding six patents. His editorial service includes roles on international journal boards such as BioMed Research International and the International Journal of Clinical and Experimental Ophthalmology, where he has reviewed more than four hundred manuscripts. Prof. Taysi’s research focuses on oxidative and nitrosative stress, the Nrf2/Keap1 pathway, and antioxidant-based therapies, integrating biochemical and molecular approaches to improve cancer treatment and radioprotection. He has 162 documents cited by 3,969 documents, with 5,099 citations and an h-index of 39, reflecting his global influence and impact in biomedical research.

Profile: Scopus | ORCID | Google Scholar

Featured Publications

Taysi, S., et al. Oxidative stress modulation in cancer therapy. Free Radical Biology & Medicine. Cited by 45 articles.

Taysi, S., et al. Phytotherapeutic agents against radiation-induced cellular damage. Antioxidants (Basel). Cited by 38 articles.

Taysi, S., et al. Nrf2/Keap1 pathway as a therapeutic target in oxidative diseases. Frontiers in Molecular Biosciences. Cited by 62 articles.

Taysi, S., et al. Role of antioxidants in radiotherapy protection. BioMed Research International. Cited by 55 articles.

Taysi, S., et al. Oxidative stress biomarkers in cancer patients. Clinical Biochemistry. Cited by 97 articles.

Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award

Published on by Molecular Biologist

Dr. Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award 

Scientific Research Lead | Memorial Sloan Kettering Cancer Center | United States

Dr. Ingrid Tatiana Erazo is a distinguished cancer researcher and Scientific Research Lead at Memorial Sloan Kettering Cancer Center (MSKCC) with extensive experience in translational oncology. She earned her PhD Summa Cum Laude in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, where she pioneered research on the ERK5 signaling pathway. Her early postdoctoral work led to the discovery of the mechanism of action for ABTL-0812, an autophagy-inducing anticancer agent now in Phase III clinical trials. Over the past decade at MSKCC, she has advanced understanding of PRMT5 inhibition, therapeutic resistance, and biomarker development for precision oncology. She currently leads initiatives integrating liquid biopsy diagnostics for early cancer detection and is spearheading global health equity programs, including the creation of Brazil’s first national referral network for cancer clinical trials. Her work bridges molecular discoveries with clinical application, driving advancements in both targeted therapies and diagnostic tools.

Professional Profile

Scopus

ORCID

Google Scholar

Education

Dr. Erazo earned her PhD in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, graduating Summa Cum Laude. Her doctoral research focused on dissecting the ERK5 signaling pathway and its role in cancer cell proliferation and survival. She used Tandem Affinity Purification to map ERK5’s interactome, uncovering novel noncanonical mechanisms and post-translational modifications such as SUMOylation that opened new therapeutic opportunities. Collaborating with Dana-Farber Cancer Institute at Harvard, she co-developed potent and selective ERK5 inhibitors, providing valuable pharmacological tools for cancer research. Her academic training combined molecular biology with translational oncology, giving her a unique foundation to move seamlessly from bench research to clinical applications. She also pursued advanced training in biomarker discovery and molecular diagnostics, enabling her to contribute to projects that merge fundamental discoveries with practical solutions for cancer detection, prognosis, and treatment optimization in a variety of clinical contexts.

Experience

Dr. Erazo’s professional career spans more than 20 completed research projects and leadership in multiple ongoing studies, covering molecular oncology, biomarker discovery, and therapeutic resistance. At MSKCC, she elucidated the mechanism of action of PRMT5 inhibitors and identified MUSASHI-2 as a driver of drug resistance in hematologic malignancies, leading to innovative combination therapy strategies. She developed liquid biopsy-based diagnostics for aggressive prostate cancers and integrated proteomic biomarkers into clinical research pipelines. In her earlier postdoctoral role at Ability Pharmaceuticals, she was instrumental in advancing ABTL-0812 to clinical trials by defining its mechanism and identifying relevant biomarkers. She has partnered with global pharmaceutical and biotech companies, including GlaxoSmithKline, Biodesix Inc., and Guardant Health. Her work also extends to global health initiatives, such as establishing Brazil’s first national referral network for cancer clinical trials with molecular profiling, aiming to address disparities in cancer care and ensure equitable access to precision oncology.

Research Interest

Dr. Erazo’s research focuses on cancer biology, mechanisms of drug resistance, biomarker discovery, and precision oncology. She has a particular interest in hematological malignancies and aggressive solid tumors where therapeutic resistance significantly impacts patient outcomes. Her work applies genome-wide CRISPR synthetic lethal screening, proteomics, and high-throughput drug screening to identify cancer vulnerabilities and inform new treatment strategies. She is advancing diagnostic methods through liquid biopsy technology, enabling early and non-invasive tumor detection and monitoring, with a focus on neuroendocrine prostate cancer. Dr. Erazo also addresses global health inequities by developing clinical trial networks in underrepresented regions and incorporating genetic ancestry into study designs to improve population-specific therapeutic approaches. By combining basic molecular research with translational and clinical applications, she aims to ensure that future cancer therapies and diagnostics are effective across diverse populations and accessible beyond high-resource healthcare settings.

Awards

Dr. Erazo’s scientific achievements have positioned her as a leader in translational cancer research and a nominee for the Molecular Biology Contribution Award. She is recognized for her groundbreaking work on ERK5 signaling, the clinical biomarker development for ABTL-0812, and the identification of MUSASHI-2 as a therapeutic resistance driver. Her contributions to liquid biopsy-based proteomic biomarkers for detecting lineage transformation in prostate cancer have advanced early diagnostic capabilities in precision oncology. She has also been a driving force behind the establishment of Brazil’s first national clinical trial referral network, demonstrating a strong commitment to global health equity. Her work, cited extensively in scientific literature, reflects both scientific rigor and real-world clinical impact. These accomplishments highlight her role as both a laboratory innovator and a global health strategist, whose research has shaped cancer treatment strategies and advanced diagnostic development on an international scale.

Top Noted Publications

Dr. Erazo has authored over 20 peer-reviewed articles in high-impact journals, including Annals of Oncology, Nature Communications, Autophagy, and Clinical Cancer Research. Her research spans mechanistic cancer biology, drug development, and biomarker-driven clinical applications. She has contributed to significant discoveries such as mapping the ERK5 interactome, elucidating the mechanism of action for ABTL-0812, and identifying resistance biomarkers for hematological malignancies. Her publications often emerge from collaborative projects that integrate molecular biology, pharmacology, and clinical trial data, reflecting her multidisciplinary approach to advancing oncology research. The high citation count of her work underscores its influence and the adoption of her findings by researchers and clinicians worldwide. Her studies have informed clinical trial design, therapeutic development, and diagnostic tool implementation, bridging the gap between basic science and patient-centered outcomes in cancer care.

Selected Publications (Single-Line Format)

Title: Erazo T, et al. The new antitumor drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels
Journal: Nature Communications
Cited by 312

Title: Erazo T, et al. Inhibition of PRMT5 in lymphomas overcomes therapeutic resistance via MUSASHI-2 modulation
Journal: Clinical Cancer Research
Cited by 145

Title: Erazo T, et al. ERK5 kinase activity-independent functions in cancer: implications for drug development
Journal: Autophagy
Cited by 110

Title: Erazo T, et al. Blood-based proteomic biomarkers for early detection of lineage plasticity in prostate cancer
Journal: Annals of Oncology
Cited by 35

Title: Erazo T, et al. High-throughput screening of FDA-approved drugs for novel therapeutic combinations in lymphoma
Journal: Molecular Oncology
Cited by 28

Conclusion

Dr. Ingrid Tatiana Erazo’s pioneering research, translational breakthroughs, and commitment to equitable precision oncology position her as an outstanding candidate for the Research for Molecular Biology Contribution Award. Her work exemplifies how rigorous molecular biology can directly shape novel therapeutics, diagnostics, and healthcare systems globally. Awarding her would recognize not only her individual achievements but also her vision for transforming cancer care through innovation and inclusivity.

 

Baran SEVEN | Molecular Biology | Best Paper Award

Published on by Molecular Biologist

Dr. Baran Seven | Molecular Biology | Best Paper Award

Doctorate | TST Fittings and Medical Devices Industry and Trade | Turkey

Dr. Baran Seven is a committed biologist whose academic journey reflects a deep focus on toxicology, molecular biology, and environmental sciences. He earned his undergraduate, master’s, and doctoral degrees in Biology from Giresun University. His research has primarily involved investigating the toxicological effects of various chemical compounds on in vivo models, particularly Swiss albino mice. Throughout his academic progression, he has actively participated in multiple national and international scientific projects, often examining the protective effects of natural plant extracts against induced toxicities. Dr. Seven has published extensively in peer-reviewed journals and has presented his findings at numerous scientific conferences. His work demonstrates an interdisciplinary approach, blending physiological, genetic, and biochemical methods to assess and mitigate toxicity. With a strong background in both laboratory research and academic collaboration, Dr. Seven continues to contribute significantly to the fields of environmental toxicology and biomedical sciences.

Professional Profile

Scopus

Education

Dr. Baran Seven completed his entire academic training in Biology at Giresun University, Turkey. He obtained his Bachelor’s degree in 2013, followed by a Master’s degree in 2015 under the supervision of Associate Professor Kültiğin Çavuşoğlu and Professor Kürşad Yapar. His master’s thesis, titled “Albino farelerde paraben tarafından teşvik edilen toksisiteye karşı ısırgan otu özütünün koruyucu rolünün araştırılması,” focused on evaluating the protective effects of nettle extract against paraben-induced toxicity in albino mice. Continuing his studies at the same institution, he earned his Ph.D. in 2022 with a dissertation entitled “Swiss albino farelerde sipermetrin toksisitesinin araştırılması: Fizyolojik, genetik ve biyokimyasal yaklaşım,” supervised by Professor Kültiğin Çavuşoğlu. His doctoral research took a multidisciplinary approach, analyzing cypermethrin-induced toxicity through physiological, biochemical, and genetic methodologies. This comprehensive education has provided Dr. Seven with a solid foundation in experimental biology and toxicology.

Experience

Dr. Baran Seven has contributed to several scientific projects, primarily in the capacity of assistant researcher. His experience includes laboratory-based toxicological studies involving Allium cepa root tip cells and Swiss albino mice. He played a central role in experiments examining the effects of ultraviolet radiation, parabens, heavy metals such as lead, and chemical agents like ammonium sulfate on genetic and physiological parameters. His involvement extended to analyzing the protective effects of natural substances, including Urtica dioica (nettle), Nigella sativa (black seed), carotene, and grape seed extract. Dr. Seven has also explored the antimicrobial and insecticidal properties of Pseudomonas species isolated from wastewater, contributing to the field of microbial biotechnology. He has consistently presented his findings at international and national congresses and has co-authored multiple scientific publications. His expertise spans DNA damage analysis, chromosomal aberration testing, and biochemical assessments, positioning him as a versatile and experienced researcher in biological sciences.

Research Interest

Dr. Baran Seven’s research interests focus on the fields of toxicology, genotoxicity, antioxidant mechanisms, and environmental biology. His primary research aims to evaluate the adverse effects of toxic chemicals such as cypermethrin, parabens, lead nitrate, bisphenol A, and various pesticides on biological systems. He employs animal models, particularly Swiss albino mice, and plant models like Allium cepa, to assess toxicity at genetic, biochemical, and physiological levels. A central theme in his work is the protective potential of natural compounds, including plant extracts and microbial isolates, against chemical-induced genotoxicity and oxidative stress. His methodologies include the use of comet assays, chromosomal aberration analysis, and biochemical marker evaluation to measure DNA damage and cellular response. Dr. Seven’s interdisciplinary approach allows him to contribute meaningfully to both the scientific understanding of toxic substances and the development of potential mitigation strategies using eco-friendly and natural agents.

Awards and Recognition

Although specific individual awards are not explicitly listed, Dr. Baran Seven’s academic profile demonstrates a strong pattern of recognition through conference participation and publication. He has been a consistent contributor to various prestigious scientific meetings, including the International Black Sea Congress on Environmental Sciences, Ecology Symposiums, and the International Anatolian Scientific Research Congress. His role in these conferences has often included presenting full-text research papers and co-authoring collaborative studies, signaling professional acknowledgment from the academic community. Additionally, his ongoing contributions to peer-reviewed journals and collaborative research projects underscore his growing influence in the field. The publication of his doctoral research in high-impact journals, such as Scientific Reports, is a testament to the quality and significance of his work. Dr. Seven’s consistent engagement with both national and international scientific forums indicates a promising academic trajectory and potential for future formal recognitions.

Top Noted Publications

Dr. Baran Seven has authored and co-authored several peer-reviewed articles in national and international journals, emphasizing toxicology, genotoxicity, and microbiology. Key publications include:

Title: Investigation of cypermethrin toxicity in Swiss albino mice with physiological, genetic and biochemical approaches
 Year: 2022
Cited by: 5 articles

Title: Effects of feeding genetically modified (GM) maize on oxidative stress parameters in New Zealand rabbit
 Year: 2018

Title: Insecticidal and Antimicrobial Effects of Pseudomonas Species Isolated From Waste Water
Year: 2022.

Title: Albino Farelerde Paraben Tarafından Oluşturulan Genotoksisitenin Araştırılması: Isırgan Otu Özütünün Koruyucu Rolü
Year: 2017

Conclusion

Dr. Baran Seven is a strong and suitable candidate for the Best Paper Award, especially for his Scientific Reports publication which reflects scientific rigor, interdisciplinary methodology, and public health relevance. His research outputs contribute significantly to the understanding of environmental toxicology and the protective role of natural compounds. With ongoing efforts toward high-impact dissemination and broader scientific visibility, Dr. Seven is poised to make continued valuable contributions to the field.